Predicted to enable phosphoribosylformylglycinamidine synthase activity. Involved in glutamine metabolic process and response to xenobiotic stimulus. Predicted to be active in cytoplasm. Biomarker of hepatocellular carcinoma. Orthologous to human PFAS (phosphoribosylformylglycinamidine synthase); PARTICIPATES IN adenine phoshoribosyltransferase deficiency pathway; adenosine monophosphate deaminase deficiency pathway; adenylosuccinate lyase deficiency pathway; INTERACTS WITH 6-propyl-2-thiouracil; amphetamine; bisphenol A.
[mono(2-ethyl-5-hydroxyhexyl) phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono(2-ethyl-5-oxohexyl)phthalate co-treated with 2-ethyl-5-carboxypentyl phthalate co-treated with mono-isobutyl phthalate co-treated with mono-benzyl phthalate co-treated with monoethyl phthalate co-treated with monobutyl phthalate] affects the expression of PFAS mRNA
[mono(2-ethyl-5-hydroxyhexyl) phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono(2-ethyl-5-oxohexyl)phthalate co-treated with 2-ethyl-5-carboxypentyl phthalate co-treated with mono-isobutyl phthalate co-treated with mono-benzyl phthalate co-treated with monoethyl phthalate co-treated with monobutyl phthalate] affects the expression of PFAS mRNA
[mono(2-ethyl-5-hydroxyhexyl) phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono(2-ethyl-5-oxohexyl)phthalate co-treated with 2-ethyl-5-carboxypentyl phthalate co-treated with mono-isobutyl phthalate co-treated with mono-benzyl phthalate co-treated with monoethyl phthalate co-treated with monobutyl phthalate] affects the expression of PFAS mRNA
[mono(2-ethyl-5-hydroxyhexyl) phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono(2-ethyl-5-oxohexyl)phthalate co-treated with 2-ethyl-5-carboxypentyl phthalate co-treated with mono-isobutyl phthalate co-treated with mono-benzyl phthalate co-treated with monoethyl phthalate co-treated with monobutyl phthalate] affects the expression of PFAS mRNA
[mono(2-ethyl-5-hydroxyhexyl) phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono(2-ethyl-5-oxohexyl)phthalate co-treated with 2-ethyl-5-carboxypentyl phthalate co-treated with mono-isobutyl phthalate co-treated with mono-benzyl phthalate co-treated with monoethyl phthalate co-treated with monobutyl phthalate] affects the expression of PFAS mRNA
[mono(2-ethyl-5-hydroxyhexyl) phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono(2-ethyl-5-oxohexyl)phthalate co-treated with 2-ethyl-5-carboxypentyl phthalate co-treated with mono-isobutyl phthalate co-treated with mono-benzyl phthalate co-treated with monoethyl phthalate co-treated with monobutyl phthalate] affects the expression of PFAS mRNA
[mono(2-ethyl-5-hydroxyhexyl) phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono(2-ethyl-5-oxohexyl)phthalate co-treated with 2-ethyl-5-carboxypentyl phthalate co-treated with mono-isobutyl phthalate co-treated with mono-benzyl phthalate co-treated with monoethyl phthalate co-treated with monobutyl phthalate] affects the expression of PFAS mRNA
[LDN 193189 co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with FGF2 protein] results in decreased expression of PFAS protein